Crinecerfont's Potential in Reducing Androgen Levels in Pediatric Congenital Adrenal Hyperplasia
|
Reviewed & Translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on September 16th, 2024
|
Congenital adrenal hyperplasia is a rare autosomal recessive disorder that impairs the synthesis of cortisol and aldosterone, leading to excessive androgen production. The Endocrine Society recommends hydrocortisone as a standard treatment, but prolonged glucocorticoid use can elevate the risk of metabolic and cardiovascular complications. To address these concerns, Neurocrine Biosciences sponsored a study to evaluate the effectiveness of crinecerfont, a corticotropin-releasing factor receptor antagonist, in managing congenital adrenal hyperplasia.
The phase 3 clinical trial enrolled 102 children aged between 2 and 17 years who were diagnosed with congenital adrenal hyperplasia. Participants were receiving glucocorticoids at an average daily dose of 16.3 mg per square meter of body surface area. Baseline biochemical assessments revealed average levels of androstenedione at 483 ng/dL and 17-hydroxyprogesterone at 9,026 ng/dL. Participants were randomly assigned to receive either a placebo or crinecerfont orally twice daily, with the crinecerfont dosage adjusted based on body weight. Concurrent use of glucocorticoids was allowed, with the dosage gradually tapered to between 8 and 10 mg per square meter per day. After the first four weeks of treatment, researchers found that crinecerfont effectively reduced serum androstenedione levels by an average of 197 ng/dL, whereas the placebo group experienced an increase in androstenedione levels. Additionally, crinecerfont decreased serum 17-hydroxyprogesterone levels by nearly 6,000 ng/dL. Analysis of adverse effects indicated that crinecerfont use was associated with an increased risk of headaches. The researchers concluded that future studies should include longer treatment and observation periods to evaluate the effects of crinecerfont on bone development and physical growth.
The phase 3 clinical trial enrolled 102 children aged between 2 and 17 years who were diagnosed with congenital adrenal hyperplasia. Participants were receiving glucocorticoids at an average daily dose of 16.3 mg per square meter of body surface area. Baseline biochemical assessments revealed average levels of androstenedione at 483 ng/dL and 17-hydroxyprogesterone at 9,026 ng/dL. Participants were randomly assigned to receive either a placebo or crinecerfont orally twice daily, with the crinecerfont dosage adjusted based on body weight. Concurrent use of glucocorticoids was allowed, with the dosage gradually tapered to between 8 and 10 mg per square meter per day. After the first four weeks of treatment, researchers found that crinecerfont effectively reduced serum androstenedione levels by an average of 197 ng/dL, whereas the placebo group experienced an increase in androstenedione levels. Additionally, crinecerfont decreased serum 17-hydroxyprogesterone levels by nearly 6,000 ng/dL. Analysis of adverse effects indicated that crinecerfont use was associated with an increased risk of headaches. The researchers concluded that future studies should include longer treatment and observation periods to evaluate the effects of crinecerfont on bone development and physical growth.